Biotechnology & Life Sciences Global On demand · 24-48h

Global Adult Preventable Vaccines Market Strategic Research Report

Global Adult Preventable Vaccines Market Strategic Research …
$3,500 USD
Market Research Reports
Strategic Research Report
Global Adult Preventable Vaccines Market
$22.14B2025
5.3%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Inactivated Vaccines, Subunit Vaccines, Mrna Vaccines, Viral Vector Vaccines, Peptide Vaccines

By Application: Prevent Influenza, Prevent Pneumococcal Infection, Prevent Hepatitis B, Prevent Herpes Zoster, Prevent Human Papillomavirus (Hpv), Other

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), Sanofi Pasteur, Moderna, Inc., Serum Institute of India Pvt., Bharat Biotech International, CSL Limited (Seqirus), Emergent BioSolutions Inc., Daiichi Sankyo Company, Novavax, Inc., Sinovac Biotech, Sinopharm Group Co., Johnson & Johnson (Janssen), AstraZeneca plc

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 113 pages
Market size 2025
$22.14B
Billion USD
Forecast CAGR
5.3%
2025-2032
Forecast 2032
$31.8B
Projected
リージョン
5
Asia Pacific · Latin America · MEA · Europe · North America

概観

Scope of the Report

The global Adult Preventable Vaccines market size is predicted to grow from US$ 22,140 million in 2025 to US$ 31,550 million in 2032; it is expected to grow at a CAGR of 5.3% from 2026 to 2032.

Adult preventable vaccines are immunizations designed to protect adults from common or high-risk infectious diseases. These vaccines aim to prevent the onset and spread of illnesses such as influenza, pneumonia, shingles, hepatitis B, and COVID-19 by boosting immunity in adults. They are particularly crucial for older individuals, those with chronic conditions, and immunocompromised populations. Adult vaccination is a vital public health strategy for maintaining individual health and controlling disease transmission within communities.

Global key Adult Preventable Vaccines players cover Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), Sanofi Pasteur, Moderna, Inc., etc.

Key Questions Addressed in this Report

What is the 10-year outlook for the global Adult Preventable Vaccines market?

What factors are driving Adult Preventable Vaccines market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Adult Preventable Vaccines market opportunities vary by end market size?

How does Adult Preventable Vaccines break out by Type, by Application?

This report presents a comprehensive overview of the global Adult Preventable Vaccines market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Inactivated Vaccines
  • Subunit Vaccines
  • Mrna Vaccines
  • Viral Vector Vaccines
  • Peptide Vaccines

Segment by Application

  • Prevent Influenza
  • Prevent Pneumococcal Infection
  • Prevent Hepatitis B
  • Prevent Herpes Zoster
  • Prevent Human Papillomavirus (Hpv)
  • Other

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Adult Preventable Vaccines market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Prevent Influenza, Prevent Pneumococcal Infection, Prevent Hepatitis B evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Adult Preventable Vaccines Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 5.3%
Regional growth momentum
Market share by segment
Key metrics
Base value
$22.14B
2025
Forecast
$31.8B
2032
CAGR
5.3%
2025–2032
リージョン
5
global
Key companies
Pfizer Inc.Merck & Co., Inc.GlaxoSmithKline plc (GSK)Sanofi PasteurModerna, Inc.Serum Institute of India Pvt.Bharat Biotech InternationalCSL Limited (Seqirus)
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Inactivated VaccinesSubunit VaccinesMrna VaccinesViral Vector VaccinesPeptide Vaccines
By Application
Prevent InfluenzaPrevent Pneumococcal InfectionPrevent Hepatitis BPrevent Herpes ZosterPrevent Human Papillomavirus (Hpv)Other

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Inactivated Vaccines
  • 3.1.3 Subunit Vaccines
  • 3.1.4 Mrna Vaccines
  • 3.1.5 Viral Vector Vaccines
  • 3.1.6 Peptide Vaccines
  • 3.1.7 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Prevent Influenza
  • 4.1.3 Prevent Pneumococcal Infection
  • 4.1.4 Prevent Hepatitis B
  • 4.1.5 Prevent Herpes Zoster
  • 4.1.6 Prevent Human Papillomavirus (Hpv)
  • 4.1.7 Other
  • 4.1.8 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Pfizer Inc.
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Merck & Co., Inc.
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 GlaxoSmithKline plc (GSK)
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 Sanofi Pasteur
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Moderna, Inc.
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Serum Institute of India Pvt.
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Bharat Biotech International
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 CSL Limited (Seqirus)
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Emergent BioSolutions Inc.
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Daiichi Sankyo Company
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Novavax, Inc.
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 Sinovac Biotech
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Sinopharm Group Co.,
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Johnson & Johnson (Janssen)
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 AstraZeneca plc
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Adult Preventable Vaccines market?
The global Adult Preventable Vaccines market is estimated at US$ 22.14 billion in 2025 (base year) and is projected to reach US$ 31.55 billion by 2032.
What is the forecast CAGR for the Adult Preventable Vaccines market?
The market is expected to grow at a CAGR of 5.3% from 2026 to 2032, expanding from US$ 22.14 billion in 2025 to US$ 31.55 billion in 2032, roughly 1.4 times its base-year value.
What is Adult Preventable Vaccines?
Adult preventable vaccines are immunizations designed to protect adults from common or high-risk infectious diseases. These vaccines aim to prevent the onset and spread of illnesses such as influenza, pneumonia, shingles, hepatitis B, and COVID-19 by boosting immunity in adults. They are particularly crucial for older individuals, those with chronic conditions, and immunocompromised populations.
How is the Adult Preventable Vaccines market segmented by type?
By type, the market is segmented into Inactivated Vaccines, Subunit Vaccines, Mrna Vaccines, Viral Vector Vaccines and Peptide Vaccines.
What are the key applications of Adult Preventable Vaccines?
Key applications covered include Prevent Influenza, Prevent Pneumococcal Infection, Prevent Hepatitis B, Prevent Herpes Zoster, Prevent Human Papillomavirus (Hpv) and Other.
Which companies are profiled in the Adult Preventable Vaccines market report?
Key players profiled include Pfizer Inc., Merck & Co., GlaxoSmithKline plc (GSK), Sanofi Pasteur, Moderna, Serum Institute of India Pvt., Bharat Biotech International and CSL Limited (Seqirus), among 15 companies covered in total.
What geographies does the Adult Preventable Vaccines market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Adult Preventable Vaccines?
What factors are driving Adult Preventable Vaccines market growth, globally and by region?
Who should buy the Adult Preventable Vaccines market report?
The report is intended for manufacturers and solution providers, distributors and end users in Prevent Influenza, Prevent Pneumococcal Infection and Prevent Hepatitis B, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Adult Preventable Vaccines market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from $3,500.00
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.